TME Pharma Partners With Aimed Analytics To Advance AI-Driven Cancer Drug Development

TME Pharma N.V., a clinical-stage biotechnology enterprise, develops TME-targeted novel treatments for cancer therapies. The company addresses cancer by focusing on targets of tumour microenvironment (TME) and partnered with Aimed Analytics, a leading medical data analytics company. This partnership supports a strategic plan. On December 4, 2024, Pharma reviled its strategic plan while targeting improvements to its capability profile for potential strategic partners. 

Aram Mangasarian, CEO of TME Pharma, said in a statement, "The 2024 Nobel Prize in Chemistry was awarded for AI-based models that allow remarkable prediction of molecular structures. This technology can also discover new drugs and improve versions of existing drugs. We believe the collaboration with aimed analytics will further advance our strategic vision announced last December. By combining our expertise in developing oligonucleotide drugs, cancer biology and immune-oncology with aimed analytics' cutting-edge capabilities, we aim to integrate AI- and Deep Learning-driven insights into our drug discovery capabilities." 

He also commented, "The goal of this collaboration is to allow TME Pharma to bring its existing drugs to the table for strategic partners and the potential for rapid and efficient discovery of new drugs. We are committed to delivering on the goals of our new strategy announced in December 2024 and plan to share further information about our progress in the coming weeks." 

Through their collaborative agreement, the partners plan to combine artificial intelligence algorithms to develop next-generation drug candidates without needing time and resource-intensive laboratory testing. The collaboration will utilise the latest AI and establish a platform to speed up research processes and decrease financial expenses and the need for experimental infrastructure. 

"We are excited to partner with TME Pharma and contribute our deep-learning and structural modelling expertise to their innovative approach to cancer treatment. By enabling a comprehensive search for promising therapeutic compounds and bringing a new level of technological sophistication to TME Pharma's drug discovery efforts, we aim to accelerate the discovery of more effective treatments and potentially lead to breakthrough therapies for patients in need,” said Dr Patrick Günther, CEO of aimed analytics.